Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Muti Abulafi"'
Publikováno v:
The Lancet Regional Health. Europe, Vol 23, Iss , Pp 100518- (2022)
Summary: Background: The UK National Institute for Health and Care Excellence (NICE), recommended in 2017 the use of the faecal immunochemical test (FIT) to guide investigations in patients presenting with NICE-defined low-risk symptoms suspicious fo
Externí odkaz:
https://doaj.org/article/fc384a38e90149b98376ef9d0aa657e8
Autor:
Theo Georgiou Delisle, Nigel D'Souza, Bethan Davies, Sally Benton, Michelle Chen, Helen Ward, Muti Abulafi, The NICE FIT Steering Committee
Publikováno v:
BJGP Open, Vol 6, Iss 1 (2022)
Background: Recent evidence suggests that the faecal immunochemical test (FIT) can rule out colorectal cancer (CRC) in symptomatic patients. To date, there is no research on usability and perception of FIT for these patients. Aim: To measure variatio
Externí odkaz:
https://doaj.org/article/65de2e1791b24c8caa3af47aff4997f5
Publikováno v:
BMJ Open, Vol 10, Iss 10 (2020)
Introduction Tumour deposits (TDs) are a poor prognostic marker when seen on pathology, and are worse than lymph node metastases (LNMs). They are now being reported on MRI as discontinuous nodules of extramural venous invasion but this diagnosis has
Externí odkaz:
https://doaj.org/article/f364287f52e34c9e9f8d4f8c4aeb292b
Autor:
Theo Georgiou Delisle, Nigel D'Souza, Jessica Tan, Ahmad Najdawi, Michelle Chen, Helen Ward, Muti Abulafi
Publikováno v:
Colorectal Disease. 24:1526-1534
To determine the efficacy of a new 2-week wait pathway that uses the faecal immunochemical test (FIT) in primary care to triage patients with high and low risk symptoms suspicious of colorectal cancer (CRC). This service improvement pilot follows 201
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:385-394
PURPOSE Extramural venous invasion (EMVI) is recognized as a poor prognostic factor in rectal cancer. There are well-documented limitations associated with pathology detection of EMVI, including variable reporting and the inability to use it preopera
Publikováno v:
Colorectal Disease. 23:2539-2549
Aim Detection of early onset colorectal cancer is challenging, and remains a rare diagnosis amongst younger people with gastrointestinal symptoms. We investigated whether faecal immunochemical testing (FIT) could identify younger patients at higher r
Autor:
Brendan Moran, Annabel Shaw, Gina Brown, Amy Lord, Paris P. Tekkis, Nigel D'Souza, Muti Abulafi, Nigel Day
Publikováno v:
European Journal of Surgical Oncology. 47:2093-2099
Introduction The incidence and patterns of local recurrence of colon cancer are not well reported. The aim of this study was to investigate the contemporary rates and patterns of local recurrence after sigmoid cancer resection, comparing pre and post
Autor:
Muti Abulafi, Nigel D'Souza
Publikováno v:
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and IrelandREFERENCES. 24(12)
Autor:
Nigel D'Souza, Michelle Zhiyun Chen, Sally C Benton, Georgina Hicks, Theo Georgiou Delisle, Muti Abulafi
Publikováno v:
Colorectal Disease. 23:1630-1638
The aim of this work was to investigate whether the faecal immunochemical test (FIT) could safely rule out colorectal cancer (CRC) in patients with rectal bleeding (RB).This was a multicentre, double-blinded diagnostic accuracy study in 50 National H
Autor:
Susanna Slater, Annette Bryant, Maria Aresu, Ruwaida Begum, Hsiang-Chi Chen, Clare Peckitt, Retchel Lazaro-Alcausi, Paul Carter, Gayathri Anandappa, Shelize Khakoo, Graham Branagan, Nicol George, Muti Abulafi, Sarah Duff, Nicholas West, Leslie Bucheit, Thereasa A. Rich, Ian Chau, Naureen Starling, David Cunningham
Publikováno v:
Journal of Clinical Oncology. 41:169-169
169 Background: Absence of post-operative ctDNA identifies resected CRC pts with low recurrence risk for potential adjuvant chemotherapy (ACT) de-escalation. We present the largest resected CRC cohort with plasma-only MRD detection, facilitating fast